doxium and retinopathy in diabetic patients

Evaluation of the effect of doxium on vision and macular thickness in patients with mild to moderate diabetic retinopathy

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20220817055729N1

Enrollment

Registered

2023-01-17

Start date

2022-09-23

Completion date

Unknown

Last updated

2023-02-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic retinopathy. Retinal disorders in diseases classified elsewhere

Interventions

Intervention 1: 50 mg of oral capsule doxium (Om Pharma, Switzerland) once a days for 180 days (maximum duration of intervention is 180 days). Intervention 2: Control group: simulating placebo capsul

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients with non-proliferative diabetic retinopathy

Exclusion criteria

Exclusion criteria: other systemic disease except for diabetes Other comorbid conditions such as CNV, RVO, Glaucoma etc. Pregnancy Lactation The history of severe psychiatric illnesses such as schizophrenia, mood disorders, borderline disorders.

Design outcomes

Primary

Measure	Time frame
Macular thickness. Timepoint: before and 6 months of treatment. Method of measurement: Macular OCT (Optical Coherence Tomography).;Visual Equity. Timepoint: before and 6 months of treatment. Method of measurement: Snellen chart.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMorteza Salimi

Oroumia University of Medical Sciences

Morteza.salimi@gmail.com+98 44 3193 7331

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026